Featured Press Releases
ICER Publishes Final Evidence Report and Policy Recommendations on Therapies for Atopic Dermatitis
Given uncertainty about safety data on oral JAK inhibitors for other indications, a narrow majority of the independent appraisal committee voted that the current evidence is adequate to demonstrate that abrocitinib, baricitinib, and upadacitinib provide a net health benefit.
08/17/2021ICER Publishes Final Evidence Report and Policy Recommendations on Aducanumab for Alzheimer’s Disease
Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net health benefit.
08/05/2021ICER Analytics™ Launched to Accelerate the Real-World Application of ICER Reports, Helping Payers, the Life Science Industry, and Health Care Policy Makers Move From Insight to Action
ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices.
11/30/2020